## AAPG: Ascentage Pharma Group Internat - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -6.0% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($27.38)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%**
- Source: GlobeNewswire | 20251209T000859 | Bullish | Relevance: 98%
-  Ascentage Pharma presented the first dataset from the global registrational Phase III POLARIS-1 study of Olverembatinib (HQP1351) in combination with low-intensity chemotherapy for newly diagnosed Ph+ ALL. The data showed a best minimal residual disease (MRD) negativity rate of 66.0% and an MRD-negative complete response (CR) rate of 64.2% by the end of 3 induction cycles, alongside a favorable safety profile. The study highlights Olverembatinib's potential to reshape the therapeutic landscape for Ph+ ALL and was recently cleared by the U.S. FDA and European Medicines Agency (EMA).

**2. ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP**
- Source: www.yourcentralvalley.com | 20251209T000859 | Bullish | Relevance: 98%
- Ascentage Pharma presented four-year follow-up data from its Phase II study of Olverembatinib at the ASH 2025 Annual Meeting. The data reconfirm Olverembatinib's long-term efficacy and safety in patients with TKI-resistant/intolerant chronic-phase chronic myeloid leukemia (CML-CP), including those without the T315I mutation. The drug showed a significantly longer event-free survival compared to best available therapy and a favorable safety profile with a 7% vascular occlusion rate.

**3. ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances**
- Source: GlobeNewswire | 20251208T012125 | Bullish | Relevance: 97%
-  Ascentage Pharma announced promising data from a Phase Ib/II study of Lisaftoclax (APG-2575) in combination with azacitidine (AZA) for patients with newly diagnosed or venetoclax-exposed myeloid malignancies. The study showed preliminary evidence of Lisaftoclax overcoming venetoclax resistance with an overall response rate of 31.8% in venetoclax-exposed patients and an 80% ORR in newly diagnosed high-risk MDS/CMML, alongside a strong safety profile. These results highlight Lisaftoclax's potential as a new treatment option for AML and HR MDS.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Oppenheimer | $45 | $0 | 0% |
| 2025-11-24 | Truist Securiti | $51 | $0 | 0% |
| 2025-11-10 | BTIG | $50 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Oppenheimer | init | Outperform |
| 2025-11-24 | Truist Securiti | init | Buy |
| 2025-11-10 | BTIG | init | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 0.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- UBS Group AG: 0.0% (+149.4%)
- XY Capital Ltd: 0.0% (+224.1%)
- Point72 (DIFC) Ltd: 0.0% (-14.2%)
- Tema Etfs LLC       : 0.0% (-33.0%)
- ABC Arbitrage SA: 0.0% (+100.0%)

### Key Risks

1. Long-term trend broken: trading 5.6% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Revenue growth strong at 244% YoY. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.8B |
| Beta | 1.11 |
| 52W Range | $16.50 - $48.45 |
| Short Interest | 0.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 improving modestly (+1.0% over 5 days). Below STRENGTH zone by 9.0pp (needs >3.0% for momentum thesis). Below SMA200 (0.94x), long-term trend not supportive.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -6.01% (CS: 5) | Weak |
| RSI_14 | 39.8 | Neutral |
| MACD Histogram | 0.02 | Bullish |
| vs SMA20 | 0.938x | Below |
| vs SMA50 | 0.877x | Below |
| vs SMA200 | 0.944x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $30.06
- **Stop Loss:** $27.38 (8.9% risk)
- **Target:** $32.74 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 111
- **Position Value:** $3,336.66
- **Portfolio %:** 3.34%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-03-26 (Est: $0.00)

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*